Pre-Made Eramkafusp Alfa Biosimilar, Fusion Protein targeting MS4A1/CD20 fused with human IFNA2 (interferon alpha 2) via a peptidyl linker: Recombinant therapeutic protein targeting B1/Bp35/CVID5/FMC7/LEU-16/S7 is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Eramkafusp Alfa is an anti-(human CD20 antigen) fusion protein with interferon alpha2b (human). Type I interferons (IFN¦Á/¦Â) are cytokines with a broad spectrum of antitumor activities including antiproliferative, proapoptotic, and immunostimulatory effects, and are potentially useful in the treatment of B-cell malignancies and other cancers. Eramkafusp Alfa is used to improve antitumor potency and diminish the systemic side effects of IFN.